Figure 3.
Mean (SE) change from baseline in EQ-VAS scores throughout the 2-year extension (part B) phase of CARDINAL, and at the ET/SFU follow-up visit, 9 weeks after cessation of sutimlimab treatment. BL, baseline.
Mean (SE) change from baseline in EQ-VAS scores throughout the 2-year extension (part B) phase of CARDINAL, and at the ET/SFU follow-up visit, 9 weeks after cessation of sutimlimab treatment. BL, baseline.
